Cancer Specialists

Helping You Provide the Best Possible Diagnosis

Historically, cancer has been diagnosed using histopathology, which has well known limitations as tumors of similar grade can display very different biological behaviors

Innovations in technology have recently advanced gene expression as a key molecular marker for the diagnostic and prognostic assessment of cancer. With next generation sequencing of RNA (RNA-Seq), it’s now possible to examine the entire cancer transcriptome that includes expression level of all genes, their transcript variants and analysis of the mutational landscape. This provides unprecedented insight into tumour biology.

iTP Biomedica is a diagnostics company that was jointly launched by Mount Sinai Services and Mount Sinai Hospital’s Lunenfeld Tanenbaum Research Institute, one of the leading research institute’s in the world. Our proprietary bioinformatics platform handles massive data sets to deliver a functional readout of the entire genome that consists of 20,000+ genes and their associated cellular networks. This provides superior molecular tools to help deliver the most accurate diagnoses possible.

Our team consists of leading researchers, clinicians and urologists who are internationally renowned in cancer diagnoses and care. Our laboratories have received ISO15189 accreditation, the College of American Pathologists (CAP) Laboratory Accreditation and the CLIA (Clinical Laboratory Improvement Act) certification. This means clinicians across North America can turn to iTP diagnostic tools to help provide their patients with the most accurate diagnoses possible.

Initial Focus on Bladder Cancer

iTP’s initial cancer diagnostic, BladderPredict™ was developed to meet the unmet demand for diagnostic tools in the bladder cancer clinic. Why bladder cancer?

  • Five-year survival rates in bladder cancer are not improving.
  • Prior to BladderPredict™, there was no tissue-based molecular test that assessed tumour aggressiveness.
  • In 2004 the grading system was changed from a 3 grade system (grade 1, 2 and 3, 1973 WHO classification) into a 2 grade system (low grade vs high grade). Too many non-muscle invasive tumors were being classified as grade 2 due to pathologist uncertainty as to whether a tumour was truly grade 1 or grade 3. As a result, the intermediate grade (grade 2), which was the subject of controversy and very important inter observer variability, was eliminated. However, while the 2004 WHO classification (low grade vs high grade) has better reproducibility than the WHO 1973 classification, its prognostic value is quite poor.
  • Even with the WHO grading system, discrepancy in grade assignment remains. While 70% of tumours are originally diagnosed as Low Grade and indolent, and 30% are High Grade (aggressive and can spread), inter-observer variability remains in up to 40% of cases.

BladderPredict™ is a laboratory-developed test (LDT) that will, for the first time, provide a molecular classification of non-muscle invasive bladder cancer using next generation sequencing (Liu et al., Eur. Urol.). When used in conjunction with classical pathology, BladderPredict™ identifies tumours that may be at risk of following a more aggressive clinical course.

In a sample size of almost 200 patients with non-muscle invasive bladder cancer tumours, analysis of the whole transcriptome by BladderPredict™ properly identified tumours that followed a more aggressive clinical trajectory.

In addition to its unprecedented accuracy, BladderPredict™ is easy to order and use.

  1. Complete the BladderPredict™ requisition form.
  2. Ensure the requisition form is signed by the Oncologist or Surgeon.
  3. Attach the original pathology report to the requisition form.
  4. Fax both to Mount Sinai Services Inc. at 647-826-1524.

For more information about BladderPredict™ and how it can help you provide your patients with the most accurate diagnoses possible, please contact

Contact iTP: Ken Hughes - - (416) 702-1187